Ulcerative Colitis Clinical Trials in Boston, Massachusetts

10 studies are recruiting for ulcerative colitis in Boston, Massachusetts right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

   This phase Ib trial studies the side effects of nivolumab and to see how well it works alone and in combination with other treatments, such as ipilimumab, cabozantinib, platinum containing therapy, and fluoropyrimidine, in treating patients with autoimmune disorders and cancer that has spread from …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Massachusetts General Hospital Cancer Center, Boston, Massachusetts

   Locations

   52 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT03816345 on ClinicalTrials.gov

2. LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:

   The main purpose of the study is to evaluate the effectiveness and safety of LY4268989 when given with mirikizumab compared to mirikizumab alone in adult participants with moderately to severely active ulcerative colitis (UC). Study participation will last approximately 118 weeks, including 104 wee…

   Stage

   Phase 2

   Ages

   18 to 80

   Site

   Brigham and Women's Hospital, Boston, Massachusetts

   Locations

   147 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07186101 on ClinicalTrials.gov

3. A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis

   This is a Phase 2, multicenter, proof-of-concept platform study in adult participants with moderately to severely active ulcerative colitis (UC). The primary goal of the study is to assess the efficacy and safety of multiple interventions following intravenous (IV) induction and subcutaneous (SC) m…

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Site 003, Boston, Massachusetts

   Locations

   267 in total

   Run by

   Spyre Therapeutics, Inc.

   See if you can join NCT07012395 on ClinicalTrials.gov

4. A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

   The main purpose of this study is to evaluate the long-term efficacy of mirikizumab in pediatric participants with ulcerative colitis (UC) or Crohn's disease (CD). The study will last about 172 weeks and may include up to 44 visits. Additional treatment may be available to participants via a Contin…

   Stage

   Phase 3

   Ages

   2 to 19

   Site

   Boston Children's Hospital, Boston, Massachusetts

   Locations

   68 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT04844606 on ClinicalTrials.gov

5. An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

   This is a multinational, multicenter, randomized, double-blind, placebo-controlled, Phase 3 induction study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Ulcerative Colitis (UC). Study details include: The study duration may be up to 35 weeks wi…

   Stage

   Phase 3

   Ages

   16 to 80

   Site

   Tufts Medical Center - Site Number: 8400126, Boston, Massachusetts

   Locations

   219 in total

   Run by

   Sanofi

   See if you can join NCT07184996 on ClinicalTrials.gov

6. A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis

   The purpose of this study is to determine the safety, efficacy, and pharmacokinetics (PK) of etrasimod for the treatment of moderately to severely active ulcerative colitis in adolescents (≥ 12 years up to < 18 years of age). Participants who will complete the total 52-week treatment period will ha…

   Stage

   Phase 2

   Ages

   12 to 17

   Site

   Boston Children's Hospital, Boston, Massachusetts

   Locations

   45 in total

   Run by

   Pfizer

   See if you can join NCT05287126 on ClinicalTrials.gov

7. A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

   The study is an extension of two parent studies (MLN0002-3024 [NCT04779307] and MLN0002-3025 [NCT04779320]). Participants must have participated in one of the previous studies. The purpose of this study is to collect the long-term safety of vedolizumab in children with UC or CD.

   Stage

   Phase 3

   Ages

   2 and older

   Site

   Boston Children's Hospital - PIN, Boston, Massachusetts

   Locations

   98 in total

   Run by

   Takeda

   See if you can join NCT05442567 on ClinicalTrials.gov

8. A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis

   This is a phase 2b, randomized, double-blind, 3-arm study for the treatment of Ulcerative Colitis. The primary objective of this study is to assess the efficacy of different doses of SAR442970 compared with placebo in participants with moderate to severe Ulcerative Colitis. The total study duration…

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Investigational Site Number: 8400017, Boston, Massachusetts

   Locations

   67 in total

   Run by

   Sanofi

   See if you can join NCT06975722 on ClinicalTrials.gov

9. Hyperbaric Oxygen Therapy for Ulcerative Colitis (HBOT-UC)

   Chronic intestinal hypoxia and accompanying mucosal inflammation is a hallmark of ulcerative colitis (UC). Hyperbaric oxygen therapy (HBOT) involves breathing 100% oxygen under increased atmospheric pressure to increase tissue oxygenation. Two small prospective randomized controlled trials have dem…

   Stage

   Not phased

   Ages

   18 to 85

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Locations

   13 in total

   Run by

   Northwestern University

   See if you can join NCT05987852 on ClinicalTrials.gov

10. High Dose Interval Vitamin D Supplementation in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy

    The investigators will be administering oral high dose interval vitamin D, concurrently when participants are receiving biologic therapy for their inflammatory bowel disease. The investigators will be collecting some additional bloodwork and questionnaires at the time of participants infusions.

    Stage

    Not phased

    Ages

    5 to 25

    Site

    Boston Children's Hospital, Boston, Massachusetts

    Run by

    Boston Children's Hospital

    See if you can join NCT04331639 on ClinicalTrials.gov